Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of MGV354 in Ocular Hypertension or Glaucoma
NCT02743780Phase 2Completed
- Sponsor
- Alcon Inc.
- Start
- Mar 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of MGV354 in ocular hypertension, open-angle glaucoma (OAG), sponsored by Alcon Inc.. Started Mar 2016; status: completed.
02
Drugs
MGV354
03
Conditions
ocular hypertensionopen-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT02743780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02743780.